Special Issue

Nanocarriers in Cancer Therapy

Message from the Guest Editor

Nanocarriers are emerging as a powerful tool in cancer therapy, offering the targeted delivery of therapeutic agents while minimizing side-effects. These nanoscale delivery systems—including organic and inorganic nanoparticles—are engineered to improve the solubility, stability, and bioavailability of anticancer drugs. One of their major advantages is the ability to selectively accumulate in tumour tissues through the enhanced permeability and retention (EPR) effect. Moreover, nanocarriers can be functionalized with ligands, such as antibodies or peptides or other motifs, to target specific tumour cell receptors, enabling active targeting and further enhancing drug accumulation in cancerous tissues. Despite their promise, the clinical translation of nanocarriers faces challenges including large-scale manufacturing, reproducibility, and regulatory approval. Nevertheless, several nanocarrier-based drugs, like Doxil® and Abraxane®, are already FDA-approved, highlighting their potential in advancing precision oncology and improving the efficacy of cancer treatments.

Guest Editor

Dr. Wenyi Gu

Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD 4072, Australia

Deadline for manuscript submissions

30 June 2026

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/243094

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)